A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.
about
Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomesSecond-generation antipsychotics for major depressive disorder and dysthymiaChallenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved TherapeuticsEfficacy, quality of life, and acceptability outcomes of atypical antipsychotic augmentation treatment for treatment-resistant depression: protocol for a systematic review and network meta-analysisSecond Generation Antipsychotics in the Treatment of Major Depressive Disorder: An UpdateEmerging targets for antidepressant therapiesNovel targets for antidepressant therapiesFluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data.A neurobiological hypothesis of treatment-resistant depression - mechanisms for selective serotonin reuptake inhibitor non-efficacy.A systematic review of duloxetine and venlafaxine in major depression, including unpublished data.Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era.Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorderEffects of quetiapine on sleep architecture in patients with unipolar or bipolar depression.Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature.Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder.Striatal dopamine D2/3 receptor availability in treatment resistant depressionWorld Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care.Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines.Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.Chronic olanzapine activates the Stat3 signal transduction pathway and alters expression of components of the 5-HT2A receptor signaling system in rat frontal cortex.Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis.Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis.The art of prescribing. Monotherapy antidepressant: a thing of the past? Implications for the treatment of major depressive disorder.Combined treatments for major depression.A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depressionAugmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder.A review of antidepressant therapy in primary care: current practices and future directions.A review of quetiapine in combination with antidepressant therapy in patients with depression.Sleep architecture in ziprasidone-treated bipolar depression: a pilot study.Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues.Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility.Current evidence for aripiprazole as augmentation therapy in major depressive disorder.Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.Efficacy and safety of olanzapine/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials.The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments.Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression.Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed.Therapeutic options in treatment-resistant depression.Targeting treatment-resistant depression.Emerging drugs for major depressive disorder.
P2860
Q21144599-03FA9980-7C6B-4E9B-8CAB-77DAB5EDCFE6Q24235667-276AD748-C3A6-4C4F-8CF4-751AFC72A720Q26782997-FB9E13F0-6CC6-4746-969F-073F94661FBCQ26828452-CDA943E6-2801-46A6-BC7E-6B9B459FFAFAQ28076712-A8C193D4-8950-461E-9567-D1C8B020130AQ28247614-E7F51781-799D-49D5-80D2-FA8BDE78AB31Q28648254-329B1D36-5F82-405C-9123-F9DCEE89BA85Q33488312-A2A0528F-CAC5-4CBC-90E5-E98DA1D68BD2Q33658525-0C99060C-5906-495F-999E-13DE0E698D0FQ33689953-65E5E1D0-23B5-42FD-A4B8-12925F58CDF8Q33716723-6CB16856-71E4-4BF6-9492-7A8CFCDCD5F7Q34010693-99B01A0A-4470-4DF2-A5BD-C8FF7DE5F0E0Q34122966-B192BD2F-4F98-4F0C-931F-43420B2EC5E2Q34330761-F994E062-24DA-4067-B330-CF21545CEC87Q34393030-289A4EAD-35CF-480F-848F-576EEA8D68F9Q34550088-707D44BC-20F8-4EE8-AA5C-8095E1538305Q34578945-3DE89C51-12F4-470B-AE3B-4803C99CBEB9Q34590507-801A260B-1B61-4821-B0F7-CE5BA8B9E671Q36091234-640629DF-62D6-4D0D-B14E-0536D7AFC0CCQ36137345-3C1FA09C-EB8D-46BD-811E-88C440F89FCEQ36236193-04946A36-5050-406C-A4B5-ACAFD53A21F2Q36588685-9CBE64A2-1D0D-4F66-A2B9-5EF90CF72B39Q36852137-EBFD7296-0BEE-4FA0-BC7D-98111F11124EQ36916862-3149BF31-C8DF-4273-BDB3-6CBD4AAEA12BQ36938416-97154489-EFF1-4A99-A6BD-4772996C3F4DQ37055322-A8DDB0D4-C630-4B5B-99CA-F506D11263E4Q37070398-8C05B9DA-39AC-4653-9E40-271556CAD9BBQ37129835-D156359B-9C94-4588-A6F5-B7BE205E59CFQ37248118-34E5D47C-7A52-44FD-BC65-8B1097028241Q37252495-884CCD24-B1F6-4F7D-9F8F-906F4620C8FEQ37256691-6F5E9C5B-4586-4603-97F8-301DD2DE7291Q37301196-5CD51D23-2B47-4B76-8B49-857C7ADA37E4Q37387345-159594DD-8DA9-46F8-9538-32FAEF4EA992Q37682874-EB736651-0F36-4F3E-AFAD-360AFE52DB82Q37709437-4A6D0093-9736-4BA1-A14B-C58A9C16B142Q37737291-ACE37557-9C3C-43D1-B790-958043C67201Q37777006-F04893F9-77D7-42B6-A4C5-EB2703348FDCQ37881968-656145BF-9758-4DE2-BBE3-49E185D0A4A2Q37957770-25997225-4829-43C5-8177-038570D76D6DQ37984619-53E49A7B-6603-4DBD-B931-FAFDE7F22D78
P2860
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
A randomized, double-blind com ...... reatment-resistant depression.
@en
A randomized, double-blind com ...... reatment-resistant depression.
@nl
type
label
A randomized, double-blind com ...... reatment-resistant depression.
@en
A randomized, double-blind com ...... reatment-resistant depression.
@nl
prefLabel
A randomized, double-blind com ...... reatment-resistant depression.
@en
A randomized, double-blind com ...... reatment-resistant depression.
@nl
P2093
P356
P1476
A randomized, double-blind com ...... reatment-resistant depression.
@en
P2093
Doug Williamson
Gary Tollefson
Michael Case
Sara A Corya
Susan D Briggs
Todd M Sanger
P304
P356
10.1002/DA.20130
P577
2006-01-01T00:00:00Z